Xiao-Yan Wu1, Song-Nan Li1, Song-Nan Wen1, Jun-Gang Nie1, Wen-Ning Deng1, Rong Bai1, Nian Liu1, Ri-Bo Tang1, Ting Zhang1, Xin Du1, Jian-Zeng Dong1, Chang-Sheng Ma2. 1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, No. 2, Anzhen Road, Beijing 100029, China. 2. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, No. 2, Anzhen Road, Beijing 100029, China chshma@vip.sina.com.
Abstract
AIMS: This study sought to explore the relationship between plasma galectin-3 (Gal-3) and persistent atrial fibrillation (PsAF), and investigate whether Gal-3 predicts clinical outcomes in patients with PsAF undergoing catheter ablation. METHODS: Fifty consecutive PsAF patients without coexisting structural heart disease undergoing first-time catheter ablation and 46 healthy controls were included. Blood samples were collected on admission for analysis of plasma Gal-3. Pre-ablation clinical and laboratory data were also recorded. Persistent atrial fibrillations patients were followed after ablation and AF recurrence was defined as episodes of AF or atrial tachycardia lasting >30 s after the blanking period. RESULTS: Plasma Gal-3 concentrations were higher in PsAF patients than in healthy controls (P < 0.001). In PsAF group, those with AF recurrence had higher plasma Gal-3 than did those without recurrence (P = 0.007). Both Gal-3 (hazard ratio 1.28, P = 0.006) and left atrial diameter (LAD) (hazard ratio 1.1, P = 0.025) were independent predictors of AF recurrence after ablation. Moreover, adding Gal-3 to LAD had an incremental predictive value for ablation outcomes (global χ(2) of LAD alone: 8.2; LAD and Gal-3 concentrations: 15.7; P = 0.006). CONCLUSION: Plasma Gal-3 concentrations are elevated in PsAF patients without structural heart disease and independently predict AF recurrence after ablation. Plasma Gal-3 concentration may be helpful in identifying appropriate candidates for AF ablation. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: This study sought to explore the relationship between plasma galectin-3 (Gal-3) and persistent atrial fibrillation (PsAF), and investigate whether Gal-3 predicts clinical outcomes in patients with PsAF undergoing catheter ablation. METHODS: Fifty consecutive PsAF patients without coexisting structural heart disease undergoing first-time catheter ablation and 46 healthy controls were included. Blood samples were collected on admission for analysis of plasma Gal-3. Pre-ablation clinical and laboratory data were also recorded. Persistent atrial fibrillationspatients were followed after ablation and AF recurrence was defined as episodes of AF or atrial tachycardia lasting >30 s after the blanking period. RESULTS: Plasma Gal-3 concentrations were higher in PsAF patients than in healthy controls (P < 0.001). In PsAF group, those with AF recurrence had higher plasma Gal-3 than did those without recurrence (P = 0.007). Both Gal-3 (hazard ratio 1.28, P = 0.006) and left atrial diameter (LAD) (hazard ratio 1.1, P = 0.025) were independent predictors of AF recurrence after ablation. Moreover, adding Gal-3 to LAD had an incremental predictive value for ablation outcomes (global χ(2) of LAD alone: 8.2; LAD and Gal-3 concentrations: 15.7; P = 0.006). CONCLUSION: Plasma Gal-3 concentrations are elevated in PsAF patients without structural heart disease and independently predict AF recurrence after ablation. Plasma Gal-3 concentration may be helpful in identifying appropriate candidates for AF ablation. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ruth Saez-Maleta; Ana Merino-Merino; Simon Gundin-Menendez; Ricardo Salgado-Aranda; Daniel AlKassam-Martinez; Virginia Pascual-Tejerina; Javier Martin-Gonzalez; Javier Garcia-Fernandez; Jose-Angel Perez-Rivera Journal: Mol Biol Rep Date: 2021-01-23 Impact factor: 2.316
Authors: Nisha Bansal; Leila R Zelnick; Elsayed Z Soliman; Amanda Anderson; Robert Christenson; Christopher DeFilippi; Rajat Deo; Harold I Feldman; Jiang He; Bonnie Ky; John Kusek; James Lash; Stephen Seliger; Tariq Shafi; Myles Wolf; Alan S Go; Michael G Shlipak Journal: Am J Kidney Dis Date: 2020-12-09 Impact factor: 11.072
Authors: Gordon A Begg; Rashed Karim; Tobias Oesterlein; Lee N Graham; Andrew J Hogarth; Stephen P Page; Christopher B Pepper; Kawal Rhode; Gregory Y H Lip; Arun V Holden; Sven Plein; Muzahir H Tayebjee Journal: PLoS One Date: 2018-01-02 Impact factor: 3.240
Authors: Yoshio Takemoto; Rafael J Ramirez; Miki Yokokawa; Kuljeet Kaur; Daniela Ponce-Balbuena; Mohamad C Sinno; B Cicero Willis; Hamid Ghanbari; Steven R Ennis; Guadalupe Guerrero-Serna; Bettina C Henzi; Rakesh Latchamsetty; Roberto Ramos-Mondragon; Hassan Musa; Raphael P Martins; Sandeep V Pandit; Sami F Noujaim; Thomas Crawford; Krit Jongnarangsin; Frank Pelosi; Frank Bogun; Aman Chugh; Omer Berenfeld; Fred Morady; Hakan Oral; José Jalife Journal: JACC Basic Transl Sci Date: 2016-04